Dashboard
With ROE of 12.8, it has a Very Expensive valuation with a 1 Price to Book Value
- The stock is trading at a fair value compared to its peers' average historical valuations
- Over the past year, while the stock has generated a return of -25.65%, its profits have risen by 4.4% ; the PEG ratio of the company is 1.9
Despite the size of the company, domestic mutual funds hold only 0% of the company
Below par performance in long term as well as near term
Total Returns (Price + Dividend) 
Latest dividend: 2.4 per share ex-dividend date: Aug-05-2025
Risk Adjusted Returns v/s 
Returns Beta
News
Alembic Pharmaceuticals receives USFDA approval for Tretinoin Cream USP, 0.05%
Alembic Pharmaceuticals receives USFDA approval for Tretinoin Cream USP, 0.05% Business Standard...
Read More Announcements 
Announcement under Regulation 30 (LODR)-Newspaper Publication
11-Jun-2026 | Source : BSEPlease find enclose herewith paper cuttings of newspaper advertisement issued regarding another special window opened for transfer and dematerialization of physical securities.
Announcement under Regulation 30 (LODR)-Newspaper Publication
09-Jun-2026 | Source : BSEplease find attached herewith a copy of the advance notice published in compliance with the procedure prescribed vide various circulars issued from time to time by MCA and SEBI inter alia informing the members about the 119th Annual General Meeting of the Company and sharing the procedure to register / update their details.
Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015
05-Jun-2026 | Source : BSEPlease find enclosed herewith the specimen copy of the reminder letter sent to the shareholders holding shares in physical form for updating their KYC details.
Corporate Actions 
No Upcoming Board Meetings
Alembic Ltd has declared 120% dividend, ex-date: 05 Aug 25
Alembic Ltd has announced 2:10 stock split, ex-date: 26 Sep 06
Alembic Ltd has announced 1:1 bonus issue, ex-date: 27 Sep 13
No Rights history available
Quality key factors 
Valuation key factors
Technicals key factors
Shareholding Snapshot : Mar 2026
Shareholding Compare (%holding) 
Promoters
None
Held by 1 Schemes (0.0%)
Held by 41 FIIs (1.25%)
Nirayu Private Limited (63.06%)
None
22.13%
Quarterly Results Snapshot (Consolidated) - Mar'26 - YoY
YoY Growth in quarter ended Mar 2026 is -0.38% vs 22.90% in Mar 2025
YoY Growth in quarter ended Mar 2026 is -1.93% vs -5.13% in Mar 2025
Half Yearly Results Snapshot (Consolidated) - Sep'25
Growth in half year ended Sep 2025 is 1.84% vs 50.03% in Sep 2024
Growth in half year ended Sep 2025 is 7.52% vs 30.93% in Sep 2024
Nine Monthly Results Snapshot (Consolidated) - Dec'25
YoY Growth in nine months ended Dec 2025 is 11.34% vs 49.04% in Dec 2024
YoY Growth in nine months ended Dec 2025 is 3.32% vs 23.30% in Dec 2024
Annual Results Snapshot (Consolidated) - Mar'26
YoY Growth in year ended Mar 2026 is 8.16% vs 40.89% in Mar 2025
YoY Growth in year ended Mar 2026 is 2.16% vs 15.66% in Mar 2025